NCT00872716 (QUISS) is a Phase 2 clinical trial of Quetiapine XR in Specific Phobia, sponsored by University Hospital Muenster.

Who is sponsoring NCT00872716?

NCT00872716 is sponsored by University Hospital Muenster.

What drugs are being tested in NCT00872716?

Interventions in NCT00872716: Quetiapine XR, Placebo.

What condition does NCT00872716 study?

NCT00872716 studies Specific Phobia.

Is NCT00872716 still recruiting?

NCT00872716 is currently completed. Last updated 30 March 2011.

Last reviewed 2011-03-30 · How we verify

NCT00872716: QUISS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anxiolytic Effects of Single-dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia

Completed Phase 2 Last updated 30 March 2011

What this trial tests

Phase 2 trial testing Quetiapine XR in Specific Phobia in 60 participants. Completed in 1 March 2011.

Timeline

1 April 2009

Primary endpoint
1 March 2011

1 March 2011

Quick facts

Lead sponsor	University Hospital Muenster
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Enrollment	60
Start date	1 April 2009
Primary completion	1 March 2011
Estimated completion	1 March 2011
Sites	1 location across Germany

Drugs / interventions tested

Quetiapine XR
Placebo

Conditions studied

Specific Phobia — all drugs for Specific Phobia →

Sponsor

University Hospital Muenster

Who can join

Adults 18 to 70, any sex, with Specific Phobia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

VAS-Anxiety
Time frame: on study day

Sponsor's own description

The study hypothesis is that quetiapine XR has anxiolytic properties. The study aims to investigate the putative anxiolytic properties of quetiapine XR in patients with anxiety disorders. Therefore, in a proof-of-concept design patients with simple phobia will be selected to investigate specific anxiolytic and antipanic activity during acute anxiety. Moreover, in a combined fMRI/visual stimulus presentation paradigm activity of fear-network associated brain structures such as the amygdala will be investigated under treatment with quetiapine XR or placebo. Additionally, genetic factors potentially mediating anxiolytic properties of quetiapine will be studied.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Quetiapine XR

Trials testing the same drug.

NCT04513912 — A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participa · Phase 3 · completed
NCT03321526 — A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjuncti · Phase 2 · completed

Other recruiting trials for Specific Phobia

Currently open trials in the same condition.

NCT07228143 — Stepped Care Treatment for Anxiety Resilience · NA · recruiting
NCT06661460 — Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders · NA · recruiting
NCT06942429 — Stepped Versus Stratified Care for Anxiety Disorders in Youth · NA · recruiting
NCT06788119 — Analyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders · NA · recruiting
NCT04563390 — Effectiveness of a Projection-based Augmented Reality Exposure System in Treating Cockroach Phobia. · NA · recruiting

Other University Hospital Muenster trials

Trials by the same sponsor.

NCT07414498 — MICRO-SURG: Subgingival Microbiome in Peri-Implantitis, Regenerative, and Resective Periodontal Surgery · NA · not yet recruiting
NCT06999174 — Multiparametric MRI for Characterization of Hepatocellular Carcinoma · recruiting
NCT06980740 — Video-Tumorboard PLUS · recruiting
NCT06648733 — Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care · NA · recruiting
NCT06464302 — Investigation of the Effect of Age and Injury Severity on Short-term Intra-hospital Outcomes After Surgical Stabilized R · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00872716 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Muenster
Last refreshed: 30 March 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00872716.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing